Biotech Values

[DewDiligence]

Today’s negative Eliquis news is exactly what I expected—from #msg-68244368 (paragraph B):

Eliquis’ phase-3 trial called ADOPT is completed and due to report data soon (http://clinicaltrials.gov/ct2/show/NCT00457002); I consider this Eliquis trial a longshot due to the poor risk-reward tradeoff in this indication and the prior failure of Xarelto.

Bottom line: No need for me to revise any of the arithmetic in #msg-68244368 on the competitive threat to Lovenox from the new oral anticoagulants.